Home › Funds › Uniplan Investment Counsel, Inc. › SRTA
Uniplan Investment Counsel, Inc. position in SRTA
STRATA CRITICAL MEDICAL INC · Health Care
Uniplan Investment Counsel, Inc. reported holding 1,453,614 shares of SRTA (STRATA CRITICAL MEDICAL INC) in its Q3 2026 13F filing — a position valued at US$7.4M, representing 0.73% of its reported portfolio and ranking #32 among its reported holdings. Uniplan Investment Counsel, Inc. has disclosed SRTA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Uniplan Investment Counsel, Inc.'s SRTA position evolved
Uniplan Investment Counsel, Inc. first disclosed a stake in SRTA in Q3 2023 at 705,094 shares (US$1.8M). The position peaked in Q2 2026 at 1,429,514 shares, worth US$7.5M. Across 13 filings, Uniplan Investment Counsel, Inc. increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,453,614 shares valued at US$7.4M — an increase of 24,100 shares quarter over quarter.. Notable position changes include a 49% increase in Q1 2024 (shares rose 22% over the following quarter), a 44% trim in Q2 2024 (shares fell 16% over the following quarter), a 78% increase in Q1 2025 (shares rose 48% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 705.09K | $1.85M | New |
| Q4 2023 | 1.01M | $3.65M | Add |
| Q1 2024 | 1.51M | $4.30M | Add |
| Q2 2024 | 844.83K | $2.94M | Reduce |
| Q3 2024 | 1.04M | $3.06M | Add |
| Q4 2024 | 973.74K | $4.14M | Reduce |
| Q1 2025 | 1.73M | $4.72M | Add |
| Q2 2025 | 1.36M | $5.49M | Reduce |
| Q3 2025 | 1.27M | $6.41M | Reduce |
| Q4 2025 | 1.26M | $6.08M | Hold |
| Q1 2026 | 1.30M | $5.44M | Add |
| Q2 2026 | 1.43M | $7.53M | Add |
| Q3 2026 | 1.45M | $7.43M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SRTA and 13F data
SRTA (STRATA CRITICAL MEDICAL INC) is a Health Care company. 39 other funds we track also report a position in SRTA — the largest reported positions include Third Point (US$26.4M), Third Point LLC (US$26.4M), Northern Right Capital Management, L.P. (US$25.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SRTA
- Third Point 5.00M sh · $26.35M · Q2 2026
- Third Point LLC 5.00M sh · $26.35M · Q2 2026
- Northern Right Capital Management, L.P. 4.89M sh · $25.77M · Q2 2026
- AWM Investment Company, Inc. 2.82M sh · $14.87M · Q2 2026
- HURRICANE CAPITAL ADVISORS LLC 2.26M sh · $11.91M · Q2 2026
- Pillsbury Lake Capital LLC 2.17M sh · $11.44M · Q2 2026
- Creek Drive Management Group LLC 736.00K sh · $3.76M · Q3 2026
More on Uniplan Investment Counsel, Inc.
FAQ
How long has Uniplan Investment Counsel, Inc. held SRTA?
Uniplan Investment Counsel, Inc. has disclosed SRTA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Uniplan Investment Counsel, Inc.'s current position in SRTA?
As of Q3 2026, Uniplan Investment Counsel, Inc. holds 1.45M shares of SRTA (STRATA CRITICAL MEDICAL INC), valued at $7.43M, representing 0.73% of its reported portfolio and ranking #32.
Has Uniplan Investment Counsel, Inc. been buying or selling SRTA?
In the latest 13F filing (Q3 2026), Uniplan Investment Counsel, Inc. increased its position in SRTA. The position peaked in Q2 2026 at 1.43M shares.
Which other funds hold SRTA?
Other major institutional holders of SRTA include Third Point, Third Point LLC, Northern Right Capital Management, L.P., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.